We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
CytRx RNAi Subsidiary Announces RNAi Licensing Agreement with Cold Spring Harbor Laboratory
News

CytRx RNAi Subsidiary Announces RNAi Licensing Agreement with Cold Spring Harbor Laboratory

CytRx RNAi Subsidiary Announces RNAi Licensing Agreement with Cold Spring Harbor Laboratory
News

CytRx RNAi Subsidiary Announces RNAi Licensing Agreement with Cold Spring Harbor Laboratory

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CytRx RNAi Subsidiary Announces RNAi Licensing Agreement with Cold Spring Harbor Laboratory"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CytRx Corporation has announced that its majority-owned subsidiary, RXi Pharmaceuticals Corporation (RXi), has secured a non-exclusive, worldwide research and therapeutic license from Cold Spring Harbor Laboratory to their short hairpin RNAi technology (shRNAi).

According to CytRx, the licensed technology potentially allows for the triggering of RNA interference (RNAi) and includes the use of short hairpin RNAis (shRNAis) either delivered as RNA compositions or encoded by DNA constructs. Patents covering this technology are currently pending. Financial terms were not disclosed for competitive reasons.

“With this license for all human therapeutic areas, we gain the well-validated advantage of shRNAi – which is reported to be up to 10- to 100-fold more potent compared with standard siRNA,” said Tod Woolf, Ph.D., RXi's President and CEO.

“This license supports our activities to accumulate a broad technology portfolio of RNA chemistry, and configuration and delivery technology, and marks another step in our construction of a world-class RNAi therapeutics company,” Woolf continued.

The technology licensed by RXi was developed in the laboratory of Gregory J. Hannon, Ph.D., a Howard Hughes Medical Institute Investigator at Cold Spring Harbor Laboratory. Dr. Hannon, who is a co-founder and member of RXi’s scientific advisory board, is also a leading expert on oncogene pathways and was formerly an advisor to Alnylam Pharmaceuticals.

Advertisement